浙江视方极

Zhejiang Shifangji Pharmaceutical Technology is a China-based biotechnology company specializing in the research and development of innovative ophthalmic drugs. Founded in 2021 and headquartered in Hangzhou, the company focuses on high-prevalence eye conditions including myopia, presbyopia, and dry eye syndrome. Its lead candidate, SFJ-001, is a small molecule therapy currently in clinical development for the treatment of myopia in children. Shifangji aims to leverage its expertise in ocular drug delivery and pharmacology to create next-generation eye care solutions that improve patient outcomes. The company has secured significant funding from leading investors such as Sequoia China and GL Ventures to accelerate its clinical pipeline.